格隆汇2月6日丨天士力(600535.SH)公布2025年度业绩快报，2025年，公司正式成为华润三九旗下一 员，以创新驱动开启融合发展新篇章，顺利完成与华润三九的"百日融合"并稳步推动"首年融合"各项工 作，在业务稳定、团队稳定、客户稳定基础上，以"四个重塑"为指引，加快与华润三九的资源整合。面 对医药行业集采控费等政策因素影响，公司持续聚焦心血管及代谢、神经/精神、消化三大治疗领域， 积极推进核心业务，全面提升企业效益效率和竞争力，坚持创新驱动，实现高质量发展，向"成为中国 医药市场的领先企业"的目标稳步迈进。报告期内，公司实现营业总收入82.36亿元，同比减少3.08%； 实现归属于上市公司股东的净利润11.05亿元，同比增加15.68%。从变动幅度上看，公司营业收入同比 下降的主要原因是医药商业收入（主要为连锁药店业务）受"门诊统筹"等行业性政策的影响同比减少 14.24%。 ...

Group 1 - The core theme of the current capital market is the protection of investors' rights, with recent initiatives from the China Securities Regulatory Commission and the Shanghai Stock Exchange emphasizing high-quality development as the best return for investors [1][2] - During the "14th Five-Year Plan" period, listed companies distributed a total of 10.6 trillion yuan to investors, representing an increase of over 80% compared to the previous five-year period, which is 2.07 times the amount raised through IPOs and refinancing [2] - Tianjin Tasly Pharmaceutical's performance forecast indicates an expected net profit of 1.105 billion yuan for 2025, a year-on-year increase of 15.68%, and basic earnings per share of 0.74 yuan, reflecting the company's commitment to high-quality development and improved investor returns [2] Group 2 - Tianjin Tasly is actively integrating with China Resources Sanjiu, focusing on "value reshaping," "business reshaping," "organizational reshaping," and "spiritual reshaping" to enhance its management system [3] - The company is optimizing its operations and management while leveraging the resources of China Resources to enhance its competitive advantage [3] - In the marketing sector, the company is collaborating with China Resources to innovate retail models and strengthen strategic partnerships with leading pharmacy chains [4]

天士力公告称，2025年度公司实现营业总收入82.36亿元，同比减少3.08%；归属于上市公司股东的净利 润11.05亿元，同比增加15.68%。公司已正式成为华润三九旗下一员，完成"百日融合"并推进"首年融 合"工作。营业收入下降主因医药商业收入受"门诊统筹"等政策影响同比减少14.24%。以上数据为初步 核算，未经审计，与最终数据或有差异。 ...

Core Viewpoint - The recent suspension of procurement qualifications for three major drug products will significantly impact the market strategies and sales expectations of three pharmaceutical companies: China Resources Sanjiu, Jiangsu Zhengda Qingjiang Pharmaceutical, and Tibet Qizheng Tibetan Medicine [1][3][18] Group 1: Impact on Companies - The suspension affects commonly used drugs for cold treatment, osteoarthritis, and external pain relief, disrupting the market plans of the involved companies [3][18] - China Resources Sanjiu's strategy to leverage the sales of Xiao Chai Hu Granules as a key growth driver is now hindered, requiring a reassessment of their market approach [7][18] - Jiangsu Zhengda Qingjiang Pharmaceutical holds a dominant market share of 96.54% for Glucosamine Hydrochloride Tablets, which is crucial for their revenue stability; the suspension will force them to adjust their market strategy [11][12][18] - Tibet Qizheng Tibetan Medicine's core product, Pain Relief Plaster, has been a significant revenue contributor, and the procurement halt will destabilize their market position, necessitating a reconfiguration of their promotional strategies [13][17][18] Group 2: Market Dynamics - Xiao Chai Hu Granules, a key OTC product, generated sales of 242 million yuan in the first three quarters of 2025, reflecting a year-on-year growth of 3.42% [4][5] - Glucosamine Hydrochloride Tablets achieved sales of 372 million yuan in the same period, marking it as a leading product in the osteoarthritis treatment category [10][11] - Pain Relief Plaster has consistently generated over 1 billion yuan in annual sales, with the first three quarters of 2025 alone exceeding 900 million yuan [16][17]

中药概念集体高开，消息面上，2026年2月5日，工业和信息化部等八部门联合发布《中药工业高质量发 展实施方案（2026—2030年）》，本文件是对2025年3月《国务院办公厅 关于提升中药质量促进中医药 产业高质量发展的意见》的分解执行。文件部署了六方面任务：原料提质稳供、协同创新攻关、制造能 力提升、民族药产业振兴、卓越企业培育。到2030年，争取推动一批中药创新药获批上市，新培育10个 中成药大品种。分批次挖掘具有突出临床价值的中成药潜力品种，培育一批新的中成药大单品。依托中 国消费名品名单等载体，有序打造中药名品方阵 中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 数据显示，截至2026年1月30日，中证中药指数(930641)前十大权重股分别为云南白药、片仔癀、东阿 阿胶、同仁堂、吉林敖东、华润三九、白云山、以岭药业、众生药业、达仁堂，前十大权重股合计占比 55.13%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 机构认为：基药目录即将出台，院内中药大单品呼之欲 ...

Core Viewpoint - The "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" aims to establish a collaborative development system for the entire industry chain by 2030, enhancing the stable supply of key raw materials, improving digital and green transformation levels, achieving breakthroughs in key technologies, and significantly increasing collaborative innovation levels [3][14]. Group 1: Development Goals - The plan sets four main goals: improving development quality, enhancing collaborative systems, fostering innovative products, and achieving breakthroughs in digital and green transformation [4][15]. - Specific tasks include cultivating 60 high-standard raw material production bases and establishing five innovation centers for the traditional Chinese medicine industry [4][15]. - The plan aims to promote the approval of innovative traditional Chinese medicine drugs and develop 10 major new traditional Chinese medicine products [4][15]. Group 2: Specific Actions - The plan outlines 15 specific tasks focusing on actions such as improving raw material quality and supply, collaborative innovation, enhancing manufacturing capabilities, revitalizing the national medicine industry, promoting traditional Chinese medicine products, and nurturing outstanding enterprises [5][16]. - It emphasizes the establishment of high-standard raw material production bases and the development of intelligent circulation and storage management systems for traditional Chinese medicine materials [7][18]. Group 3: Innovation and Technology - The plan encourages the use of artificial intelligence and big data to enhance the research and development of traditional Chinese medicine, including the creation of knowledge graphs for classic formulas and experiences from renowned practitioners [9][20]. - It also supports the clinical trials of new traditional Chinese medicine drugs and aims to shorten the research and development cycle while reducing costs [9][20]. Group 4: Market and Brand Development - The plan includes initiatives to protect intellectual property rights for traditional brands and improve the production processes of existing traditional Chinese medicine products to enhance their clinical and market value [6][17]. - It encourages collaboration between traditional Chinese medicine enterprises and e-commerce platforms to provide efficient purchasing experiences for patients [6][17].

Core Viewpoint - The article discusses the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" issued by the Ministry of Industry and Information Technology and other departments, outlining goals for the development of the traditional Chinese medicine (TCM) industry over the next five years, focusing on supply stability, innovation, and digital transformation [1][3]. Group 1: Development Goals - The plan sets four major goals for the TCM industry by 2030, including the establishment of a collaborative development system, enhanced supply capabilities of key TCM raw materials, significant improvements in digital and green levels, and breakthroughs in key technologies [1][3]. - Specific tasks include improving the quality of TCM production, enhancing the collaborative system across the supply chain, and promoting the continuous emergence of innovative TCM products [3][5]. Group 2: Specific Actions - The plan outlines 15 specific tasks across six action areas, including actions to ensure stable supply of raw materials, promote collaborative innovation, enhance manufacturing capabilities, and revitalize the national medicine industry [5][9]. - For TCM raw materials, the plan emphasizes the construction of high-standard production bases and the establishment of a smart circulation and storage management system to ensure stable supply [7][9]. Group 3: Innovation and Product Development - The plan aims to foster the development of innovative TCM products, including the approval of new TCM drugs and the cultivation of major TCM varieties [3][5]. - It encourages collaboration between TCM enterprises and e-commerce platforms to enhance patient access to TCM products and improve the clinical and market value of TCM [5][9]. Group 4: Quality and Standards - The plan includes actions to enhance the quality standards of TCM, such as the formulation of national standards for TCM decoction pieces and the establishment of a quality traceability system [8][9]. - It also highlights the importance of protecting intellectual property rights for traditional brands and improving production processes for existing TCM products [5][9].

2月5日，工业和信息化部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》（以下简称 《实施方案》）。 《实施方案》提出了未来五年的发展目标：到2030年，中药工业全产业链协同发展体系初步形成，重点 中药原料持续稳定供应能力进一步增强，数智化、绿色化水平明显提升，一批关键技术取得突破，产业 协同创新水平显著提高。 设置四大目标 根据工业和信息化部消费品工业司披露的解读，《实施方案》着力推进产业政策、监管政策、医保政策 和临床使用政策的有效协同；充分发挥地方政府发展中药工业的积极性，鼓励各地因地制宜先行先试； 将原料的持续稳定供应作为产业链供应链稳定的"牛鼻子"；将支持中药工业龙头企业发展壮大、不断提 高行业集中度作为重中之重。 《实施方案》重点围绕发展质量、协同体系、创新产品、数智化绿色化转型升级等方面设置了具体的任 务目标。 四是数智化、绿色化转型升级取得突破，制修订10项中药工业数智技术相关行业标准，推动建设一批数 智化创新载体和公共服务平台，支持企业开展数智化改造提升，发布20个数智化转型升级典型案例，建 设20个智能工厂、培育10个绿色工厂。 围绕主要目标，《实施方案》聚焦原料提质稳供 ...

2月5日，工业和信息化部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》（以下简称 《实施方案》）。 《实施方案》提出了未来五年的发展目标：到2030年，中药工业全产业链协同发展体系初步形成，重点 中药原料持续稳定供应能力进一步增强，数智化、绿色化水平明显提升，一批关键技术取得突破，产业 协同创新水平显著提高。 设置四大目标 根据工业和信息化部消费品工业司披露的解读，《实施方案》着力推进产业政策、监管政策、医保政策 和临床使用政策的有效协同；充分发挥地方政府发展中药工业的积极性，鼓励各地因地制宜先行先试； 将原料的持续稳定供应作为产业链供应链稳定的"牛鼻子"；将支持中药工业龙头企业发展壮大、不断提 高行业集中度作为重中之重。 《实施方案》重点围绕发展质量、协同体系、创新产品、数智化绿色化转型升级等方面设置了具体的任 务目标。 一是发展质量明显提高，中药工业规模效益稳步提升，产业集约化程度明显提高，质量管理水平显著提 升，培育一批引领带动能力突出的中药工业领航企业，培育60个高标准中药原料生产基地。 二是协同体系更加健全，中药材种植加工、中药研发生产、流通服务等上下游各环节协同更加紧密，建 设 ...

Core Viewpoint - The Chinese medicine ETF (560080) has shown positive performance with most constituent stocks rising, indicating a favorable market sentiment towards the Chinese medicine sector [1][6]. Group 1: Stock Performance - Major stocks in the Chinese medicine ETF have seen significant gains, with Da Ren Tang rising over 4%, Pian Zai Huang over 3%, and Tong Ren Tang over 2% [1]. - The estimated weights and performance of key stocks include: - Yunnan Baiyao at 10.56% with a 1.47% increase - Pian Zai Huang at 9.21% with a 3.78% increase - Dong E E Jiao at 6.18% with a 0.73% increase [2]. Group 2: Technological Advancements - The launch of the first "Traditional Chinese Medicine Brain-Machine Interface" equipment marks a significant technological advancement, aimed at treating neurological disorders [3]. - This technology integrates brain-machine interface with acupuncture, showcasing innovation in the field of traditional medicine [3]. Group 3: Policy Developments - The implementation of the "Drug Administration Law Implementation Regulations" emphasizes a review system for traditional Chinese medicine based on traditional theories, human experience, and clinical data [4]. - The regulations aim to ensure the safety and traceability of traditional Chinese medicine products, which may lead to industry consolidation and growth for leading companies [4]. Group 4: Investment Opportunities - Three main investment themes in the Chinese medicine sector are identified: 1. Price governance, focusing on competitive products and companies that can leverage price reductions for volume growth [5]. 2. Consumption recovery, driven by macroeconomic improvement and an aging population, benefiting companies with strong brand and product advantages [7]. 3. State-owned enterprise reform, which may enhance performance through efficiency improvements in state-controlled companies [8]. Group 5: Market Activity - The Chinese medicine ETF (560080) has seen increased trading activity, with a transaction volume nearing 1 billion yuan and significant capital inflow over recent days [6].